Oxford BioDynamics Plc receives €4 million Horizon 2020 award

Oxford BioDynamics Plc (LONOBD) today announced that it has been chosen as an industrial partner in a Horizon 2020 international research and innovation collaboration. The initiative on “Predictive Epigenetics” (PEP-NET), which has been granted €4 million, brings together an international consortium of 11 leading epigenetic research centres and five partner organisations* to develop practical translation of epigenetic regulation into therapeutically actionable outcomes.

The PEP-NET consortium comprises experimentalists and theoreticians whose goal is to develop a joint predictive modelling framework to further the understanding of fundamental epigenetic mechanisms. The outcome will present real world applications for the development of new technologies, and diagnostic and therapeutic tools to benefit patients.

This will be an important opportunity for OBD to increase utilisation of its EpiSwitch™ platform and further develop its technology globally, while helping to improve understanding of epigenetic controls and mechanisms. As an industry partner in this initiative, all parties will have access to OBD’s intellectual property for research purposes only.

Consortium member Professor Leonie Ringrose, Institute of Biology, Humboldt University, Berlin, commented:

“Epigenetic mechanisms are profoundly implicated in human health and disease. Despite the availability of large amounts of molecular data sets today, the field is still far from a satisfactory mechanistic understanding of many epigenetic processes. This unique collaboration of frontline researchers and commercial companies aims to combine quantitative experiments, predictive theoretical models, new modeling of data analysis and latest industrial tools of detection and monitoring to understand epigenetic regulation, with the aim to achieve both deeper fundamental understanding and better practical translation of epigenetic regulation into actionable patient stratifications. We have seen the practical value of EpiSwitch™ and believe this powerful platform will allow us to develop real world solutions.

PEP-NET will train a generation of European researchers to combine quantitative experiments with predictive theoretical models, and will exploit this knowledge to answer both basic and applied questions in epigenetics.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    What is EpiSwitch and how is it used?

    Grounded in Epigenetics Oxford BioDynamics’ EpiSwitch technology is based on epigenetics: mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune diseases, neurologic

    Oxford BioDynamics

    FDA publishes guidance to help in developing new ALS therapies

    After gathering input from patients, researchers, and advocates, the U.S Food and Drug Administration (FDA) has released new guidance on the development of therapies for amyotrophic lateral sclerosis (ALS). Among its recommendations, it is advising more communication with

    Oxford BioDynamics

    Qualtrax Boosts Oxford BioDynamics Efficiencies

    Businesses involved in areas such as the pharmaceutical sector must demonstrate the highest levels of compliance, traceability and quality. Given the large volumes of documents generated by such organisations, important tasks such as keeping track of

    Oxford BioDynamics

    What you need to know about rheumatoid arthritis

    Rheumatoid arthritis (RA) is a chronic disease that affects the joints throughout your body. It often starts in the hands and feet RA is an autoimmune disease, it happens when your immune system attacks your own cells. While

    Oxford BioDynamics

    Want to Slow Down Your ALS? Try Smiling!

    What does smiling have to do with ALS? Or happiness, contentment, or feeling positive? These expressions of our sense of well-being are important to those of us living with ALS. According to a study of 224 ALS patients, participants

    Oxford BioDynamics

    How does alcohol affect rheumatoid arthritis?

    Drinking alcohol in moderation is typically safe for people with rheumatoid arthritis (RA). According to the Arthritis Foundation, drinking alcohol in moderation is usually safe, and may even reduce certain types of inflammation. Some research says that small

    Oxford BioDynamics

    Ice Bucket Challenge Creator Continues To Inspire

    A Westchester man battling ALS is fighting for a cure and one way he hopes to do that is by bringing back the ice bucket challenge. Pat Quinn was diagnosed with the deadly degenerative disease in

    Oxford BioDynamics

    MND Association welcomes report on benefits and terminal illness

    A report revealing terminally ill people face devastating and far-reaching financial hardship because of a ‘made-up policy fudge’ has been welcomed by the Motor Neurone Disease (MND) Association. The All Party Parliamentary Group for Terminal Illness

    Oxford BioDynamics

    Having this temperature in your joints must NOT be ignored

    Arthritis is a type of inflammatory autoimmune disease and is a musculoskeletal condition which is caused by the body’s joints. The areas most commonly affected include the hands, fingers, hips, knees and spine. The disease commonly affects